Literature DB >> 15907869

Results of an international round robin for the quantification of serum non-transferrin-bound iron: Need for defining standardization and a clinically relevant isoform.

Esther M G Jacobs1, Jan C M Hendriks, Berry L J H van Tits, Patricia J Evans, William Breuer, Ding Yong Liu, Eugene H J M Jansen, Katri Jauhiainen, Brigitte Sturm, John B Porter, Barbara Scheiber-Mojdehkar, Leni von Bonsdorff, Z Ioav Cabantchik, Robert C Hider, Dorine W Swinkels.   

Abstract

Non-transferrin-bound iron (NTBI) appears in the circulation of patients with iron overload. Various methods to measure NTBI were comparatively assessed as part of an international interlaboratory study. Six laboratories participated in the study, using methods based on iron mobilization and detection with iron chelators or on reactivity with bleomycin. Serum samples of 12 patients with hereditary (n=11) and secondary (n=1) hemochromatosis were measured during a 3-day analysis using 4 determinations per sample per day, making a total of 144 measurements per laboratory. Bland-Altman plots for repeated measurements are presented. The methods differed widely in mean serum NTBI level (range 0.12-4.32mumol/L), between-sample variation (SD range 0.20-2.13mumol/L and CV range 49.3-391.3%), and within-sample variation (SD range 0.02-0.45mumol/L and CV range 4.4-193.2%). The results obtained with methods based on chelators correlated significantly (R(2) range 0.86-0.99). On the other hand, NTBI values obtained by the various methods related differently from those of serum transferrin saturation (TS) when expressed in terms of both regression coefficients and NTBI levels at TS of 50%. Recent studies underscore the clinical relevance of NTBI in the management of iron-overloaded patients. However, before measurement of NTBI can be introduced into clinical practice, there is a need for more reproducible protocols as well as information on which method best represents the pathophysiological phenomenon and is most pertinent for diagnostic and therapeutic purposes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15907869     DOI: 10.1016/j.ab.2005.03.008

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  24 in total

1.  Timed non-transferrin bound iron determinations probe the origin of chelatable iron pools during deferiprone regimens and predict chelation response.

Authors:  Yesim Aydinok; Patricia Evans; Chantal Y Manz; John B Porter
Journal:  Haematologica       Date:  2011-12-16       Impact factor: 9.941

2.  Second international round robin for the quantification of serum non-transferrin-bound iron and labile plasma iron in patients with iron-overload disorders.

Authors:  Louise de Swart; Jan C M Hendriks; Lisa N van der Vorm; Z Ioav Cabantchik; Patricia J Evans; Eldad A Hod; Gary M Brittenham; Yael Furman; Boguslaw Wojczyk; Mirian C H Janssen; John B Porter; Vera E J M Mattijssen; Bart J Biemond; Marius A MacKenzie; Raffaella Origa; Renzo Galanello; Robert C Hider; Dorine W Swinkels
Journal:  Haematologica       Date:  2015-09-18       Impact factor: 9.941

3.  Oxidative stress and inflammation in iron-overloaded patients with beta-thalassaemia or sickle cell disease.

Authors:  Patrick B Walter; Ellen B Fung; David W Killilea; Qing Jiang; Mark Hudes; Jacqueline Madden; John Porter; Patricia Evans; Elliott Vichinsky; Paul Harmatz
Journal:  Br J Haematol       Date:  2006-10       Impact factor: 6.998

4.  Diagnosis and management of transfusion iron overload: the role of imaging.

Authors:  John C Wood
Journal:  Am J Hematol       Date:  2007-12       Impact factor: 10.047

5.  Excessive body iron stores are not associated with risk of coronary heart disease in women.

Authors:  Qi Sun; Jing Ma; Nader Rifai; Oscar H Franco; Kathryn M Rexrode; Frank B Hu
Journal:  J Nutr       Date:  2008-12       Impact factor: 4.798

6.  Results of the first international round robin for the quantification of urinary and plasma hepcidin assays: need for standardization.

Authors:  Joyce J C Kroot; Erwin H J M Kemna; Sukhvinder S Bansal; Mark Busbridge; Natascia Campostrini; Domenico Girelli; Robert C Hider; Vasiliki Koliaraki; Avgi Mamalaki; Gordana Olbina; Naohisa Tomosugi; Chris Tselepis; Douglas G Ward; Tomas Ganz; Jan C M Hendriks; Dorine W Swinkels
Journal:  Haematologica       Date:  2009-12       Impact factor: 9.941

Review 7.  Scientific and Regulatory Considerations for Generic Complex Drug Products Containing Nanomaterials.

Authors:  Nan Zheng; Dajun D Sun; Peng Zou; Wenlei Jiang
Journal:  AAPS J       Date:  2017-01-23       Impact factor: 4.009

8.  Snapshots of Iron Speciation: Tracking the Fate of Iron Nanoparticle Drugs via a Liquid Chromatography-Inductively Coupled Plasma-Mass Spectrometric Approach.

Authors:  Heather M Neu; Sergei A Alexishin; Joel E P Brandis; Anne M C Williams; Wenjing Li; Dajun Sun; Nan Zheng; Wenlei Jiang; Ann Zimrin; Jeffrey C Fink; James E Polli; Maureen A Kane; Sarah L J Michel
Journal:  Mol Pharm       Date:  2019-02-14       Impact factor: 4.939

Review 9.  Early detection of cardiac involvement in thalassemia: From bench to bedside perspective.

Authors:  Nut Koonrungsesomboon; Siriporn C Chattipakorn; Suthat Fucharoen; Nipon Chattipakorn
Journal:  World J Cardiol       Date:  2013-08-26

Review 10.  Estimating tissue iron burden: current status and future prospects.

Authors:  John C Wood
Journal:  Br J Haematol       Date:  2015-03-12       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.